Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure
To evaluate the additive ocular hypotensive effect of latanoprost and dorzolamide in combination, on intraocular pressure reduction in patients with elevated intraocular pressure (IOP). Thirty patients with ocular hypertension or early capsular or primary open-angle glaucoma and elevated IOP were ra...
Gespeichert in:
| Veröffentlicht in: | International ophthalmology 1998, Vol.22 (1), p.37 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 37 |
| container_title | International ophthalmology |
| container_volume | 22 |
| creator | Kimal Arici, M Topalkara, A Güler, C |
| description | To evaluate the additive ocular hypotensive effect of latanoprost and dorzolamide in combination, on intraocular pressure reduction in patients with elevated intraocular pressure (IOP).
Thirty patients with ocular hypertension or early capsular or primary open-angle glaucoma and elevated IOP were randomly assigned to two parallel treatment groups. The treatment period was twenty days. Fifteen patients (Group 1) received latanoprost once daily during the first ten days and, in addition, dorzolamide three times daily during the second ten days. Fifteen patients (Group 2) received dorzolamide three times daily during the first ten days and, in addition latanoprost, once daily during the second ten days. IOP was measured and conjunctival hyperemia was evaluated.
In Group 1, the mean IOP on day 0 was 26.8 mm Hg; on day 10, 18.7 mm Hg; and on day 20, 15.9 mm Hg. In Group 2, the mean IOP on day 0 was 26.3 mm Hg; on day 10, 21.2 mm Hg; and on day 20, 16.1 mm Hg. Both groups had clinically significant IOP-lowering effect on day 10 as compared with baseline day (30.2% and 19.4% respectively) (p |
| doi_str_mv | 10.1023/A:1006176713983 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_10090447</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10090447</sourcerecordid><originalsourceid>FETCH-LOGICAL-c253t-cc8dcb0acf5ca19b7c2fc7a967e71dc4fae2625789bb6dbfd9d75087c3414fab3</originalsourceid><addsrcrecordid>eNo1j81KxDAURrNQnHF07U7yAtWkaZPGXRl0FAbc6FKGm-QGI_0jSUf06S2oq7M4hw8-Qq44u-GsFLftHWdMciUVF7oRJ2TNuKyLWjG-IucpfTDGtNLyjKyWULOqUmvy1joXcjgiRe_RZjp62kGGYZzimDKFwVE3xu-xgz44pGGgE-SAQ070M-R3ih0eIaNbTI4w2rmDSKeIKc0RL8iphy7h5R835PXh_mX7WOyfd0_bdl_Ysha5sLZx1jCwvrbAtVG29FaBlgoVd7bygKUsa9VoY6Qz3mmnatYoKyq-SCM25Pp3d5pNj-4wxdBD_Dr8_xQ_ifZWIQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Kimal Arici, M ; Topalkara, A ; Güler, C</creator><creatorcontrib>Kimal Arici, M ; Topalkara, A ; Güler, C</creatorcontrib><description>To evaluate the additive ocular hypotensive effect of latanoprost and dorzolamide in combination, on intraocular pressure reduction in patients with elevated intraocular pressure (IOP).
Thirty patients with ocular hypertension or early capsular or primary open-angle glaucoma and elevated IOP were randomly assigned to two parallel treatment groups. The treatment period was twenty days. Fifteen patients (Group 1) received latanoprost once daily during the first ten days and, in addition, dorzolamide three times daily during the second ten days. Fifteen patients (Group 2) received dorzolamide three times daily during the first ten days and, in addition latanoprost, once daily during the second ten days. IOP was measured and conjunctival hyperemia was evaluated.
In Group 1, the mean IOP on day 0 was 26.8 mm Hg; on day 10, 18.7 mm Hg; and on day 20, 15.9 mm Hg. In Group 2, the mean IOP on day 0 was 26.3 mm Hg; on day 10, 21.2 mm Hg; and on day 20, 16.1 mm Hg. Both groups had clinically significant IOP-lowering effect on day 10 as compared with baseline day (30.2% and 19.4% respectively) (p<0.01). When dorzolamide was added to latanoprost, the additional IOP reduction was 2.8 mm Hg (15%) (p<0.01) compared with 5.1 mm Hg (24.1%) (p<0.01) when latanoprost was added to dorzolamide. No local serious adverse reactions were observed. A mild but statistically significant increase in conjunctival hyperemia was seen in latanoprost applied patients.
The results showed that latanoprost and dorzolamide can be combined successfully to reduce IOP with their additive effects.</description><identifier>ISSN: 0165-5701</identifier><identifier>DOI: 10.1023/A:1006176713983</identifier><identifier>PMID: 10090447</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Adult ; Carbonic Anhydrase Inhibitors - administration & dosage ; Carbonic Anhydrase Inhibitors - therapeutic use ; Cross-Over Studies ; Drug Synergism ; Drug Therapy, Combination ; Exfoliation Syndrome - drug therapy ; Female ; Follow-Up Studies ; Glaucoma, Open-Angle - drug therapy ; Humans ; Intraocular Pressure - drug effects ; Male ; Middle Aged ; Ocular Hypertension - drug therapy ; Prostaglandins F, Synthetic - administration & dosage ; Prostaglandins F, Synthetic - therapeutic use ; Single-Blind Method ; Sulfonamides - administration & dosage ; Sulfonamides - therapeutic use ; Thiophenes - administration & dosage ; Thiophenes - therapeutic use ; Treatment Outcome</subject><ispartof>International ophthalmology, 1998, Vol.22 (1), p.37</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c253t-cc8dcb0acf5ca19b7c2fc7a967e71dc4fae2625789bb6dbfd9d75087c3414fab3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10090447$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kimal Arici, M</creatorcontrib><creatorcontrib>Topalkara, A</creatorcontrib><creatorcontrib>Güler, C</creatorcontrib><title>Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure</title><title>International ophthalmology</title><addtitle>Int Ophthalmol</addtitle><description>To evaluate the additive ocular hypotensive effect of latanoprost and dorzolamide in combination, on intraocular pressure reduction in patients with elevated intraocular pressure (IOP).
Thirty patients with ocular hypertension or early capsular or primary open-angle glaucoma and elevated IOP were randomly assigned to two parallel treatment groups. The treatment period was twenty days. Fifteen patients (Group 1) received latanoprost once daily during the first ten days and, in addition, dorzolamide three times daily during the second ten days. Fifteen patients (Group 2) received dorzolamide three times daily during the first ten days and, in addition latanoprost, once daily during the second ten days. IOP was measured and conjunctival hyperemia was evaluated.
In Group 1, the mean IOP on day 0 was 26.8 mm Hg; on day 10, 18.7 mm Hg; and on day 20, 15.9 mm Hg. In Group 2, the mean IOP on day 0 was 26.3 mm Hg; on day 10, 21.2 mm Hg; and on day 20, 16.1 mm Hg. Both groups had clinically significant IOP-lowering effect on day 10 as compared with baseline day (30.2% and 19.4% respectively) (p<0.01). When dorzolamide was added to latanoprost, the additional IOP reduction was 2.8 mm Hg (15%) (p<0.01) compared with 5.1 mm Hg (24.1%) (p<0.01) when latanoprost was added to dorzolamide. No local serious adverse reactions were observed. A mild but statistically significant increase in conjunctival hyperemia was seen in latanoprost applied patients.
The results showed that latanoprost and dorzolamide can be combined successfully to reduce IOP with their additive effects.</description><subject>Adult</subject><subject>Carbonic Anhydrase Inhibitors - administration & dosage</subject><subject>Carbonic Anhydrase Inhibitors - therapeutic use</subject><subject>Cross-Over Studies</subject><subject>Drug Synergism</subject><subject>Drug Therapy, Combination</subject><subject>Exfoliation Syndrome - drug therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glaucoma, Open-Angle - drug therapy</subject><subject>Humans</subject><subject>Intraocular Pressure - drug effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ocular Hypertension - drug therapy</subject><subject>Prostaglandins F, Synthetic - administration & dosage</subject><subject>Prostaglandins F, Synthetic - therapeutic use</subject><subject>Single-Blind Method</subject><subject>Sulfonamides - administration & dosage</subject><subject>Sulfonamides - therapeutic use</subject><subject>Thiophenes - administration & dosage</subject><subject>Thiophenes - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0165-5701</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j81KxDAURrNQnHF07U7yAtWkaZPGXRl0FAbc6FKGm-QGI_0jSUf06S2oq7M4hw8-Qq44u-GsFLftHWdMciUVF7oRJ2TNuKyLWjG-IucpfTDGtNLyjKyWULOqUmvy1joXcjgiRe_RZjp62kGGYZzimDKFwVE3xu-xgz44pGGgE-SAQ070M-R3ih0eIaNbTI4w2rmDSKeIKc0RL8iphy7h5R835PXh_mX7WOyfd0_bdl_Ysha5sLZx1jCwvrbAtVG29FaBlgoVd7bygKUsa9VoY6Qz3mmnatYoKyq-SCM25Pp3d5pNj-4wxdBD_Dr8_xQ_ifZWIQ</recordid><startdate>1998</startdate><enddate>1998</enddate><creator>Kimal Arici, M</creator><creator>Topalkara, A</creator><creator>Güler, C</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>1998</creationdate><title>Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure</title><author>Kimal Arici, M ; Topalkara, A ; Güler, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c253t-cc8dcb0acf5ca19b7c2fc7a967e71dc4fae2625789bb6dbfd9d75087c3414fab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Carbonic Anhydrase Inhibitors - administration & dosage</topic><topic>Carbonic Anhydrase Inhibitors - therapeutic use</topic><topic>Cross-Over Studies</topic><topic>Drug Synergism</topic><topic>Drug Therapy, Combination</topic><topic>Exfoliation Syndrome - drug therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glaucoma, Open-Angle - drug therapy</topic><topic>Humans</topic><topic>Intraocular Pressure - drug effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ocular Hypertension - drug therapy</topic><topic>Prostaglandins F, Synthetic - administration & dosage</topic><topic>Prostaglandins F, Synthetic - therapeutic use</topic><topic>Single-Blind Method</topic><topic>Sulfonamides - administration & dosage</topic><topic>Sulfonamides - therapeutic use</topic><topic>Thiophenes - administration & dosage</topic><topic>Thiophenes - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kimal Arici, M</creatorcontrib><creatorcontrib>Topalkara, A</creatorcontrib><creatorcontrib>Güler, C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>International ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kimal Arici, M</au><au>Topalkara, A</au><au>Güler, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure</atitle><jtitle>International ophthalmology</jtitle><addtitle>Int Ophthalmol</addtitle><date>1998</date><risdate>1998</risdate><volume>22</volume><issue>1</issue><spage>37</spage><pages>37-</pages><issn>0165-5701</issn><abstract>To evaluate the additive ocular hypotensive effect of latanoprost and dorzolamide in combination, on intraocular pressure reduction in patients with elevated intraocular pressure (IOP).
Thirty patients with ocular hypertension or early capsular or primary open-angle glaucoma and elevated IOP were randomly assigned to two parallel treatment groups. The treatment period was twenty days. Fifteen patients (Group 1) received latanoprost once daily during the first ten days and, in addition, dorzolamide three times daily during the second ten days. Fifteen patients (Group 2) received dorzolamide three times daily during the first ten days and, in addition latanoprost, once daily during the second ten days. IOP was measured and conjunctival hyperemia was evaluated.
In Group 1, the mean IOP on day 0 was 26.8 mm Hg; on day 10, 18.7 mm Hg; and on day 20, 15.9 mm Hg. In Group 2, the mean IOP on day 0 was 26.3 mm Hg; on day 10, 21.2 mm Hg; and on day 20, 16.1 mm Hg. Both groups had clinically significant IOP-lowering effect on day 10 as compared with baseline day (30.2% and 19.4% respectively) (p<0.01). When dorzolamide was added to latanoprost, the additional IOP reduction was 2.8 mm Hg (15%) (p<0.01) compared with 5.1 mm Hg (24.1%) (p<0.01) when latanoprost was added to dorzolamide. No local serious adverse reactions were observed. A mild but statistically significant increase in conjunctival hyperemia was seen in latanoprost applied patients.
The results showed that latanoprost and dorzolamide can be combined successfully to reduce IOP with their additive effects.</abstract><cop>Netherlands</cop><pmid>10090447</pmid><doi>10.1023/A:1006176713983</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-5701 |
| ispartof | International ophthalmology, 1998, Vol.22 (1), p.37 |
| issn | 0165-5701 |
| language | eng |
| recordid | cdi_pubmed_primary_10090447 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Carbonic Anhydrase Inhibitors - administration & dosage Carbonic Anhydrase Inhibitors - therapeutic use Cross-Over Studies Drug Synergism Drug Therapy, Combination Exfoliation Syndrome - drug therapy Female Follow-Up Studies Glaucoma, Open-Angle - drug therapy Humans Intraocular Pressure - drug effects Male Middle Aged Ocular Hypertension - drug therapy Prostaglandins F, Synthetic - administration & dosage Prostaglandins F, Synthetic - therapeutic use Single-Blind Method Sulfonamides - administration & dosage Sulfonamides - therapeutic use Thiophenes - administration & dosage Thiophenes - therapeutic use Treatment Outcome |
| title | Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T09%3A44%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Additive%20effect%20of%20latanoprost%20and%20dorzolamide%20in%20patients%20with%20elevated%20intraocular%20pressure&rft.jtitle=International%20ophthalmology&rft.au=Kimal%20Arici,%20M&rft.date=1998&rft.volume=22&rft.issue=1&rft.spage=37&rft.pages=37-&rft.issn=0165-5701&rft_id=info:doi/10.1023/A:1006176713983&rft_dat=%3Cpubmed%3E10090447%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/10090447&rfr_iscdi=true |